Q2 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN - Free Report) - Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for Illumina in a report released on Thursday, July 17th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will earn $1.03 per share for the quarter, up from their previous forecast of $1.02. The consensus estimate for Illumina's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina's FY2025 earnings at $4.45 EPS and Q4 2026 earnings at $1.43 EPS.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same period in the prior year, the firm posted $0.98 earnings per share. The business's quarterly revenue was down 1.4% compared to the same quarter last year.

A number of other brokerages have also weighed in on ILMN. Evercore ISI boosted their price objective on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Canaccord Genuity Group increased their price objective on Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a research note on Wednesday, June 11th. Morgan Stanley decreased their price target on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. JPMorgan Chase & Co. dropped their price target on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Finally, Barclays restated an "underweight" rating and set a $85.00 target price (up from $77.00) on shares of Illumina in a research report on Tuesday, June 24th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $125.11.

Illumina Price Performance

Illumina stock opened at $98.71 on Friday. The stock's fifty day moving average price is $88.82 and its two-hundred day moving average price is $95.45. Illumina has a one year low of $68.70 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48. The firm has a market cap of $15.63 billion, a PE ratio of -16.13, a price-to-earnings-growth ratio of 1.90 and a beta of 1.36.

Institutional Investors Weigh In On Illumina

Institutional investors and hedge funds have recently modified their holdings of the company. Capital World Investors lifted its stake in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares during the period. Vanguard Group Inc. increased its holdings in Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after purchasing an additional 558,243 shares in the last quarter. WCM Investment Management LLC grew its stake in shares of Illumina by 1.2% during the first quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after acquiring an additional 49,156 shares in the last quarter. Corvex Management LP grew its stake in shares of Illumina by 125.2% during the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock valued at $303,841,000 after acquiring an additional 2,129,449 shares in the last quarter. Finally, Brown Advisory Inc. grew its stake in Illumina by 52.1% in the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock worth $230,818,000 after purchasing an additional 996,589 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Insider Buying and Selling

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction on Monday, May 12th. The shares were bought at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.60% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.